Expression of Human Apoaii in Transgenic Rabbits Leads to Dyslipidemia A New Model for Combined Hyperlipidemia

Tomonari Koike,Shuji Kitajima,Ying Yu,Ying Li,Kazutoshi Nishijima,Enqi Liu,Huijun Sun,Ahmed Bilal Waqar,Nobumitsu Shibata,Tomoriho Inoue,Yao Wang,Bo Zhang,Junji Kobayashi,Masatoshi Morimoto,Keijiro Saku,Teruo Watanabe,Jianglin Fan
DOI: https://doi.org/10.1161/atvbaha.109.190264
2009-01-01
Abstract:Objective-Apolipoprotein AII (apoAII) is the second major apolipoprotein in high-density lipoprotein (HDL). However, the physiological functions of apoAII in lipoprotein metabolism have not been fully elucidated.Methods and Results-We generated human apoAII transgenic (Tg) rabbits, a species that normally does not have an endogenous apoAII gene. Plasma levels of human apoAII in Tg rabbits were approximate to 30 mg/dL, similar to the plasma levels in healthy humans. The expression of human apoAII in Tg rabbits resulted in increased levels of plasma triglycerides, total cholesterol, and phospholipids accompanied by a marked reduction in HDL-cholesterol levels compared with non-Tg littermates. Analysis of lipoprotein fractions showed that hyperlipidemia exhibited by Tg rabbits was caused by elevated levels of very-low-density lipoproteins (VLDL) and intermediate-density lipoproteins. Furthermore, postheparin lipoprotein lipase activity significantly decreased in Tg rabbits compared with non-Tg rabbits.Conclusions-These results indicate that apoAII plays an important role in both VLDL and HDL metabolism, possibly through the inhibition of lipoprotein lipase activity. ApoAII Tg rabbits may become a new model for the study of human familial combined hyperlipidemia. (Arterioscler Thromb Vasc Biol. 2009;29:2047-2053.)
What problem does this paper attempt to address?